Pakistan
· Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 7.94 billion. The enterprise value is 7.67 billion.
| Market Cap | 7.94B |
| Enterprise Value | 7.67B |
Important Dates
The next estimated earnings date is Friday, October 4, 2024.
| Earnings Date | Oct 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has decreased by -0.26% in one year.
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | -0.26% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 52.00% |
| Owned by Institutions (%) | 11.90% |
| Float | 106.35M |
Valuation Ratios
The trailing PE ratio is 9.84 and the forward PE ratio is 9.15.
| PE Ratio | 9.84 |
| Forward PE | 9.15 |
| PS Ratio | 0.61 |
| PB Ratio | 1.45 |
| P/FCF Ratio | 23.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.75, with an EV/FCF ratio of 22.51.
| EV / Earnings | 9.51 |
| EV / Sales | 0.59 |
| EV / EBITDA | 5.75 |
| EV / EBIT | 6.26 |
| EV / FCF | 22.51 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 24.10.
| Current Ratio | 1.36 |
| Quick Ratio | 0.70 |
| Debt / Equity | 24.10 |
| Debt / EBITDA | 0.99 |
| Debt / FCF | 3.88 |
| Interest Coverage | 28.21 |
Financial Efficiency
Return on equity (ROE) is 15.06% and return on invested capital (ROIC) is 11.65%.
| Return on Equity (ROE) | 15.06% |
| Return on Assets (ROA) | 7.44% |
| Return on Capital (ROIC) | 11.65% |
| Revenue Per Employee | 22.01M |
| Profits Per Employee | 1.36M |
| Employee Count | 594 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 3.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.25% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +71.25% |
| 50-Day Moving Average | 31.32 |
| 200-Day Moving Average | 26.88 |
| Relative Strength Index (RSI) | 60.30 |
| Average Volume (20 Days) | 2,887,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 13.07 billion and earned 805.98 million in profits. Earnings per share was 3.53.
| Revenue | 13.07B |
| Gross Profit | 1.57B |
| Operating Income | 1.22B |
| Pretax Income | 1.30B |
| Net Income | 805.98M |
| EBITDA | 1.33B |
| EBIT | 1.22B |
| Earnings Per Share (EPS) | 3.53 |
Balance Sheet
The company has 1.60 billion in cash and 1.32 billion in debt, giving a net cash position of 275.32 million or 1.21 per share.
| Cash & Cash Equivalents | 1.60B |
| Total Debt | 1.32B |
| Net Cash | 275.32M |
| Net Cash Per Share | 1.21 |
| Equity (Book Value) | 5.48B |
| Book Value Per Share | 24.00 |
| Working Capital | 1.79B |
Cash Flow
In the last 12 months, operating cash flow was 925.26 million and capital expenditures -584.65 million, giving a free cash flow of 340.61 million.
| Operating Cash Flow | 925.26M |
| Capital Expenditures | -584.65M |
| Free Cash Flow | 340.61M |
| FCF Per Share | 1.49 |
Margins
Gross margin is 12.05%, with operating and profit margins of 9.36% and 6.17%.
| Gross Margin | 12.05% |
| Operating Margin | 9.36% |
| Pretax Margin | 9.98% |
| Profit Margin | 6.17% |
| EBITDA Margin | 10.17% |
| EBIT Margin | 9.36% |
| FCF Margin | 2.61% |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 7.30%.
| Dividend Per Share | 2.50 |
| Dividend Yield | 7.30% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 70.69% |
| Buyback Yield | 0.26% |
| Shareholder Yield | 7.56% |
| Earnings Yield | 10.16% |
| FCF Yield | 4.29% |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |